Ongoing research is therefore currently exploring whether sub-phenotypes of AKI, potentially identified through novel biomarkers such as NGAL, may offer more reliable detection of AKI that overcomes the limitations of serum creatinine and correlates more closely with clinical outcomes [16, 24, 25]. This evidence concerns the gene LCN2 and acute kidney injury.